Elisabeth Kueenburg

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

Meletios Α. Dimopoulos, Katja Weisel, Niels W.C.J. van de Donk et al. · Journal of Clinical Oncology · 2018 · 71 citations · Full text

Medicine, Nephrology, Pharmacotherapy +10

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

Martin Kropff, H Baylon, Tadeusz Robak et al. · Haematologica · 2011 · 55 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Niels W.C.J. van de Donk, Rakesh Popat, Jeremy T. Larsen et al. · Blood · 2020 · 47 citations

Medicine, Pharmacology, Pharmacotherapy +14

The Effects of Ramipril on Glucose Tolerance, Insulin Secretion, and Insulin Sensitivity in Patients with Hypertension

Bernhard Ludvik, Elisabeth Kueenburg, M Brunnbauer et al. · Journal of Cardiovascular Pharmacology · 1991 · 17 citations

Medicine, Endocrinology, Pharmacology +16

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

Yan Li, Xiaomin Wang, Edward O’Mara et al. · Clinical Pharmacology Advances and Applications · 2017 · 16 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17